Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients
| dc.contributor.author | Nakou, E. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisar, M. S. | en |
| dc.date.accessioned | 2015-11-24T16:57:22Z | |
| dc.date.available | 2015-11-24T16:57:22Z | |
| dc.identifier.issn | 1465-6566 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/10574 | |
| dc.rights | Default Licence | - |
| dc.subject | hypertension | en |
| dc.subject | low-density lipoprotein cholesterol | en |
| dc.subject | low-density lipoprotein subfractions | en |
| dc.subject | obesity | en |
| dc.subject | prebetal high-density lipoprotein | en |
| dc.subject | sibutramine | en |
| dc.subject | trandolapril | en |
| dc.subject | verapamil | en |
| dc.subject | visfatin | en |
| dc.subject | coronary-artery-disease | en |
| dc.subject | plasma visfatin levels | en |
| dc.subject | weight-loss | en |
| dc.subject | waist circumference | en |
| dc.subject | phospholipase a(2) | en |
| dc.subject | randomized trial | en |
| dc.subject | heart-disease | en |
| dc.subject | double-blind | en |
| dc.subject | dense ldl | en |
| dc.subject | trandolapril | en |
| dc.title | Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients | en |
| heal.abstract | Objective: The management of obese hypertensive subjects may require the administration of anti-obesity and anti hypertensive drugs. Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate. The primary end-points of this study were an evaluation of the effect of sibutramine together with a verapamil sustained release/trandolapril combination tablet versus verapamil sustained release/trandolapril alone on the blood pressure and heart rate in obese hypertensive patients. Research design/methods: Patients received a low-fat low-calorie diet and were randomly allocated to open-label verapamil sustained release/trandolapril 180/2 mg (n = 26) or sibutramine 10 mg together with verapamil sustained release/trandolapril 180/2 mg (n = 28) daily for 6 months. Results: Significant reductions in the subjects' systolic blood pressure and diastolic blood pressure were observed in both groups (p < 0.01 versus baseline). At 6 months a greater fall in blood pressure was observed in the sibutramine/verapamil sustained release/trandolapril group compared with the verapamil sustained release/trandolapril group (systolic blood pressure 21.9 +/- 8.1 versus 15.9 +/- 12.3 mmHg and diastolic blood pressure 15.7 +/- 8.1 versus 9.1 +/- 9.9 mmHg) but this was only significant (p = 0.03) for diastolic blood pressure. The subjects' heart rate did not change significantly in any group. No significant sibutramine-associated attenuation of blood pressure reduction was observed during the study. The sibutramine/verapamil sustained release/trandolapril treatment resulted in significantly greater improvement in the subjects' anthropometric variables, homeostasis model assessment and lipid profiles compared with verapamil sustained release/trandolapril administration. The subjects' small dense low-density lipoprotein cholesterol, high-sensitivity C-reactive protein and visfatin plasma levels were only measured in the sibutramine/verapamil sustained release/trandolapril group (all decreased by p < 0.05 versus baseline). Conclusions: The sibutramine/verapamil sustained release/trandolapril combination in obese hypertensive patients significantly reduced their blood pressure and improved their anthropometric and metabolic variables without affecting the heart rate. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | Doi 10.1517/14656560802172587 | - |
| heal.identifier.secondary | <Go to ISI>://000257620100002 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/14656566.9.10.1629 | - |
| heal.journalName | Expert Opinion on Pharmacotherapy | en |
| heal.journalType | peer reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2008 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: